Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Feb 16, 2006
app pub date -
Aug 15, 2005
filing date -
Aug 13, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Methods for screening specific biological endpoints that can be utilized to identify potential therapeutic agents for METH addiction. In one aspect of the invention, the methods involve reversal of behavioral sensitization and/or conditioned place preference in an animal previously treated with METH in the presence of a known amount of a 5-HT.sub.2A/2C antagonist or a selective 5-HT.sub.2C antagonist, and reversal of the electrophysiological endpoints in a METH-treated animal in the presence of a known amount of the 5-HT.sub.2A/2C antagonist or the selective 5-HT.sub.2C antagonist. Therapeutic treatment methods for reversing the set of biological endpoints that change in the METH drug addict using mirtazapine, SDZ SER 082, and related serotonin antagonists are also provided. The methods of the invention may be utilized in the identification of potential new therapies for multiple drugs of abuse.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully